Technology area: Biotechnology & Pharmaceuticals
35 pending office actions • 27 art units • 33 examiners • 0 of 35 (0%) have an AI response strategy ready • 34 patents granted in the last 365 days
Icahn School of Medicine At Mount Sinai has 34 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 33 examiners and 27 art units, demonstrating broad technical and examiner coverage with limited concentration.
TRAN, CHRISTINA L is the busiest examiner, with 2 pending matters. The modest concentration means most prosecution work must be managed through application-specific teams rather than one examiner relationship.
The difference between examiner and art-unit counts indicates that some technical examination groups contain multiple examiner assignments. Counsel can use those shared art-unit environments to coordinate scientific positions while preserving matter-specific claim strategies.
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (6%) |
| §101 + other | 7 (20%) |
| §103 only | 4 (11%) |
| §102 only | 1 (3%) |
| §112 only | 1 (3%) |
| Double-patenting + other | 3 (9%) |
| Multi-statute (no §101) | 16 (46%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZOU, NIANXIANG | 2 | 64.0% | +25.0% |
| TRAN, CHRISTINA L | 2 | 51.6% | +49.8% |
| HENSON, DEVIN B | 1 | 65.1% | +43.4% |
| HUYNH, EMILY | 1 | 22.9% | +44.9% |
| HUSSAINI, ATTIYA SAYYADA | 1 | 61.7% | +19.5% |
| HELCO, NICHOLAS JOHN | 1 | 67.3% | +40.5% |
| HOLLAND, PAUL J | 1 | 57.3% | +64.7% |
| SALVOZA, M FRANCO G | 1 | 68.2% | +30.6% |
| BARR, MARY EVANGELINE | 1 | 36.1% | +32.5% |
| LIPPERT, JOHN WILLIAM | 1 | 59.2% | +39.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17922777 | RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SARS-COV-2-SPIKE PROTEIN AND USES THEREOF | ZOU, NIANXIANG | 30d overdue |
| 18251670 | CXCR1/CXCR2 INHIBITORS FOR USE IN TREATING MYELOFIBROSIS | SZNAIDMAN, MARCOS L | 25d overdue |
| 17778598 | SMALL UNANNOTATED, NON-CODING RNAS FOR THE DETECTION OF LIVER CANCER | VANN-OJUEKAIYE, KENDRA RAYCHELL | 6d |
| 18261907 | SYSTEMS, METHODS, AND DEVICES, FOR IMPLEMENTING INTERVENTION TREATMENT REGIMENS FOR A POPULATION OF SUBJECTS | REICHERT, RACHELLE LEIGH | 12d |
| 17781929 | METHOD OF TREATMENT WITH KCNQ CHANNEL OPENERS | TRAN, ERIC | 22d |
| 18036095 | PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES | COUGHLIN, MATTHEW P | 28d |
| 17633255 | METHOD OF TREATING KELOIDS | MIDDLETON, DANAYA L | 28d |
| 18002075 | SYSTEMS AND METHODS FOR EVALUATING A SUBJECT FOR INFLAMMATORY BOWEL DISEASE MANAGEMENT | EDOUARD, JONATHAN CHRISTOPHER | 65d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18712863 | SYSTEMS AND METHODS FOR ELECTROCARDIOGRAM DEEP LEARNING INTERPRETABILITY | BARR, MARY EVANGELINE | 97d overdue |
| 17922777 | RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SARS-COV-2-SPIKE PROTEIN AND USES THEREOF | ZOU, NIANXIANG | 30d overdue |
| 19089388 | METHODS, DEVICES, AND SYSTEMS FOR MONITORING INTRAOCULAR PRESSURE | HENSON, DEVIN B | — |
| 19107505 | Growth Assessment for Pulmonary Nodules | HUYNH, EMILY | — |
| 18866723 | Non-Invasive Intranasal Neuromodulation System | HUSSAINI, ATTIYA SAYYADA | — |
| 18918891 | SYSTEMS AND METHODS FOR IDENTIFYING PROSTATE CANCER PATIENTS AT HIGH-RISK OF PROGRESSION | HELCO, NICHOLAS JOHN | — |
| 18750693 | THERAPEUTIC ACID CERAMIDASE COMPOSITIONS AND METHODS OF MAKING AND USING THEM | HOLLAND, PAUL J | — |
| 18674423 | ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF | SALVOZA, M FRANCO G | — |
| Art Unit | Apps |
|---|---|
| 1671 | 3 |
| 1637 | 3 |
| 3683 | 2 |
| 3686 | 2 |
| 1636 | 2 |
| 1685 | 2 |
| 3791 | 1 |
| 3792 | 1 |
| 2667 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19089388 | METHODS, DEVICES, AND SYSTEMS FOR MONITORING INTRAOCULAR PRESSURE | HENSON, DEVIN B | 3791 | §102Other | Non-Final OA | — | Pending | Mar 25, 2025 |
| 19107505 | Growth Assessment for Pulmonary Nodules | HUYNH, EMILY | 3683 | §101§103 | Non-Final OA | — | Pending | Feb 27, 2025 |
| 18866723 | Non-Invasive Intranasal Neuromodulation System | HUSSAINI, ATTIYA SAYYADA | 3792 | §102§103 | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18918891 | SYSTEMS AND METHODS FOR IDENTIFYING PROSTATE CANCER PATIENTS AT HIGH-RISK OF PROGRESSION | HELCO, NICHOLAS JOHN | 2667 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18750693 | THERAPEUTIC ACID CERAMIDASE COMPOSITIONS AND METHODS OF MAKING AND USING THEM | HOLLAND, PAUL J | 1656 | §103 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18674423 | ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF | SALVOZA, M FRANCO G | 1672 | §101§112DP | Non-Final OA | — | Pending | May 24, 2024 |
| 18712863 | SYSTEMS AND METHODS FOR ELECTROCARDIOGRAM DEEP LEARNING INTERPRETABILITY | BARR, MARY EVANGELINE | 3682 | — | Final Rejection | 97d overdue | Pending | May 23, 2024 |
| 18708774 | LIQUID RADIOEMBOLIC AGENTS AND RELATED EMBOLIZATION SYSTEMS AND METHODS OF EMBOLIZATION | LIPPERT, JOHN WILLIAM | 1615 | §102§103 | Non-Final OA | — | Pending | May 09, 2024 |
| 18535430 | SYSTEMS AND METHODS FOR PROCESSING CONNECTIVITY VALUES BETWEEN SUB-PROCESSING REGIONS | SZUMNY, JONATHON A | 3686 | §103Other | Non-Final OA | 33d | Pending | Dec 11, 2023 |
| 18564527 | METHOD OF TREATING DRUG RESISTANT EPILEPSY | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103 | Final Rejection | — | Pending | Nov 27, 2023 |
| 18520481 | PROTACS WITH TRANSCRIPTION FACTOR TARGETING MOIETIES | YU, DELPHINUS DOU YI | 1636 | §103§112 | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18560052 | METHODS FOR DETECTING AND STAGING CELLULAR VIRAL IMMUNE RESPONSES | ZOU, NIANXIANG | 1671 | §103§112 | Final Rejection | — | Pending | Nov 09, 2023 |
| 18500881 | FUSION PROTEINS COMPRISING DETECTABLE TAGS, NUCLEIC ACID MOLECULES, AND METHOD OF TRACKING A CELL | D' AMBROSIO, THEA | 1654 | §102§103§112 | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18289181 | Peptides And Methods For Detecting Egg Allergies | JOHANSEN, PETER N. | 1644 | §101§102§103§112 | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18496065 | THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS FOR CANCER | GODDARD, LAURA B | 1642 | §103§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18556458 | CHIMERIC NEWCASTLE DISEASE VIRUS EXPRESSING APMV HN AND F PROTEINS | FOLEY, SHANON A | 1671 | §103§112 | Final Rejection | — | Pending | Oct 20, 2023 |
| 18261907 | SYSTEMS, METHODS, AND DEVICES, FOR IMPLEMENTING INTERVENTION TREATMENT REGIMENS FOR A POPULATION OF SUBJECTS | REICHERT, RACHELLE LEIGH | 3686 | §101 | Non-Final OA | 12d | Pending | Jul 18, 2023 |
| 18349494 | REGULATORY SYSTEM FOR EXPRESSION OF A GENE OF INTEREST IN A TARGET CELL AND METHOD OF USE THEREOF | WARD, AARON DUREL | 1636 | §103§112 | Non-Final OA | — | Pending | Jul 10, 2023 |
| 18255852 | Systems and Methods for Dynamic Raman Profiling of Biological Diseases and Disorders | STRIEGEL, THEODORE CHARLES | 1685 | §103DP | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18036095 | PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES | COUGHLIN, MATTHEW P | 1626 | §102§112 | Final Rejection | 28d | Pending | May 09, 2023 |
| 18251670 | CXCR1/CXCR2 INHIBITORS FOR USE IN TREATING MYELOFIBROSIS | SZNAIDMAN, MARCOS L | 1628 | §103§112 | Non-Final OA | 25d overdue | Pending | May 03, 2023 |
| 18034965 | METHODS OF TREATING TUMORS AND CANCERS HAVING DYSREGULATED WNT SIGNALING PATHWAYS | WHITE, DAWANNA SHAR-DAY | 1627 | §103DP | Final Rejection | 98d overdue | Pending | May 02, 2023 |
| 18030983 | COMPOSITIONS FOR TREATMENT ALOPECIA AREATA, BIOMARKERS FOR TREATMENT SUCCESS AND, METHODS OF USE THEREOF | DEBERRY, REGINA M | 1647 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 07, 2023 |
| 18246014 | ARCHAEA L30 PROTEINS AS UNIVERSAL INFLUENZA VIRUS THERAPEUTICS | TRAN, CHRISTINA L | 1637 | §112 | Non-Final OA | — | Pending | Mar 20, 2023 |
| 18002075 | SYSTEMS AND METHODS FOR EVALUATING A SUBJECT FOR INFLAMMATORY BOWEL DISEASE MANAGEMENT | EDOUARD, JONATHAN CHRISTOPHER | 3683 | §101 | Final Rejection | 65d | Pending | Dec 16, 2022 |
| 17922777 | RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SARS-COV-2-SPIKE PROTEIN AND USES THEREOF | ZOU, NIANXIANG | 1671 | §103§112 | Final Rejection | 30d overdue | Pending | Nov 01, 2022 |
| 17802789 | VEGFR-3-ACTIVATING AGENTS AND ONCOLYTIC VIRUSES AND USES THEREOF FOR THE TREATMENT OF CANCER | TRAN, CHRISTINA L | 1637 | §103§112 | Final Rejection | — | Pending | Aug 26, 2022 |
| 17759564 | CELL SPECIFIC, SELF-INACTIVATING GENOMIC EDITING USING CRISPR-CAS SYSTEMS HAVING RNASE AND DNASE ACTIVITY | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103 | Final Rejection | — | Pending | Jul 27, 2022 |
| 17781929 | METHOD OF TREATMENT WITH KCNQ CHANNEL OPENERS | TRAN, ERIC | 1629 | §103§112 | Final Rejection | 22d | Pending | Jun 02, 2022 |
| 17778598 | SMALL UNANNOTATED, NON-CODING RNAS FOR THE DETECTION OF LIVER CANCER | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103§112 | Non-Final OA | 6d | Pending | May 20, 2022 |
| 17731115 | Treatment of Mood and Anxiety Disorders | CHERNYSHEV, OLGA N | 1675 | §103§112 | Final Rejection | — | Pending | Apr 27, 2022 |
| 17769486 | SYSTEMS AND METHODS FOR DETECTING A DISEASE CONDITION | WHALEY, PABLO S | 3619 | §101§112 | Non-Final OA | — | Pending | Apr 15, 2022 |
| 17769485 | SYSTEMS AND METHODS FOR DETECTING A DISEASE CONDITION | BICKHAM, DAWN MARIE | 1685 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 15, 2022 |
| 17633255 | METHOD OF TREATING KELOIDS | MIDDLETON, DANAYA L | 1674 | §102§103§112 | Non-Final OA | 28d | Pending | Feb 07, 2022 |
| 17616626 | SYSTEMS AND METHODS FOR DIAGNOSTICS FOR BIOLOGICAL DISORDERS ASSOCIATED WITH PERIODIC VARIATIONS IN METAL METABOLISM | ZEMAN, MARY K | 1686 | §102DP | Final Rejection | 30d overdue | Pending | Dec 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIcahn School of Medicine At Mount Sinai has 35 pending office actions as of October 2026, spread across 27 art units and 33 examiners.
Nianxiang Zou has the most, with 2 of Icahn School of Medicine At Mount Sinai's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
